Togolese Professor Olivier Adotévi invents a cancer vaccine

---

Extract from the article: Nouvelle percée majeure dans le domaine en pleine effervescence des vaccins ARN anti-cancer : l’équipe du professeur Olivier Adotévi (CHU de Besançon en France et togolais d’origine), vient de publier des résultats positifs, six ans après le lancemen

---

Another major breakthrough in the rapidly expanding field of RNA cancer vaccines: the team led by Professor Olivier Adotévi (Besançon University Hospital, France, and originally from Togo) has just published positive results, six years after the launch of early-phase clinical trials in lung cancer, for its new therapeutic vaccine UCPVax, in the prestigious « Journal of clinical oncology ».

This vaccine is designed to activate immune system cells, CD4 T lymphocytes, in order to target telomerase, an enzyme responsible for the immortality of cancer cells found in the majority of cancers. Some 60 patients with advanced lung cancer who had failed treatment were treated with UCPVax. The main results demonstrate the safety, tolerability and efficacy of UCPVax. The three doses tested in this trial triggered an equivalent and effective immune response in around 80% of patients. In addition, improved survival was observed in around half of vaccine responders.

The UCPVax vaccine, manufactured at the Besançon University Hospital pharmacy and distributed to some fifteen French hospitals, is being tested in combination with other anti-cancer therapies, in various types of cancer such as glioblastoma, human papillomavirus-related cancers and even liver cancer.

Jean ELI